For the roughly 1,500 Australians diagnosed with follicular lymphoma each year, the approval of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide marks the first chemotherapy-free, dual-targeted immunotherapy option for relapsed or refractory disease. The Therapeutic Goods Administration (TGA) decision on April 23, 2026, covers Grade 1-3a R/R FL after at least one prior therapy.
The regimen leverages tafasitamab's CD19 targeting alongside rituximab's CD20 blockade, with lenalidomide as an immunomodulatory backbone. In the pivotal L-MIND trial (NCT02399085), the combo achieved an overall response rate of 72% and a median duration of response of 43.9 months in R/R FL patients. The safety profile was consistent with known toxicities, including neutropenia and infections.
Competitive landscape: CAR-Ts and bispecifics loom
The R/R FL treatment space has become increasingly crowded. Gilead/Kite's Yescarta (axicabtagene ciloleucel) and Novartis' Kymriah are approved for R/R FL after two or more prior lines, while Roche's Lunsumio (mosunetuzumab) and Genentech's mosunetuzumab (bispecific CD20xCD3) offer off-the-shelf alternatives. Tafasitamab's advantage lies in its dual-targeting mechanism and manageable toxicity, but it requires combination therapy and has not been directly compared head-to-head against CAR-T or bispecifics.
Pricing and reimbursement will be critical. In Australia, the Pharmaceutical Benefits Scheme (PBS) listing is pending; without subsidy, the cost of tafasitamab (estimated at ~$15,000 per cycle) may limit uptake. The L-MIND data also showed a median progression-free survival of 11.1 months, which, while meaningful, trails the 40-month median PFS seen with Yescarta in the ZUMA-5 trial.
For investors, the approval is a modest positive for MorphoSys (now part of Novartis after the $2.7B acquisition in 2024) and Incyte, which commercializes tafasitamab outside the US. However, the R/R FL market is fragmenting, and tafasitamab's role may be as a bridge to cellular therapies or for patients ineligible for CAR-T. The real test will be whether the combination can secure reimbursement and whether ongoing trials in earlier lines (e.g., first-line FL) can expand the addressable population.
